AstraZeneca-Daiichi Sankyo’s Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo (OTC:DSNKY) (OTC:DSKYF) shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine…
Resilience To Establish A Biomanufacturing Partnership With AstraZeneca And Purchase AstraZeneca’s Manufacturing Site In West Chester, Ohio
Long-term partnership to be established between Resilience and AstraZeneca for the biomanufacturing of established and emerging modalities.
West Chester, Ohio site will become Resilience's global center of
AstraZeneca to Acquire Neogene Therapeutics for Up to $320M
Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), today announced it has entered into a definitive agreement to be acquired by AstraZeneca.
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ:AZN) worth up to $402…
C4X Discovery Holdings Signed Exclusive Global License Worth up to $402M with AstraZeneca for the Development and Commercialization of NRF2 Activator Program
C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing."
The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.
“Health And Human Services Report Says Mask Mandates Should Be Reinstated To Help ‘Long Covid'” – NYPost
Not this again.
Masks and social distancing should be mandated or encouraged in public to protect people from possible “long COVID”, a new Department of Health and Human Services report
AstraZeneca to Present New Data Advancing Its Ambition to Redefine Care at the 2022 San Antonio Breast Cancer Symposium; Twelve Medicines and Potential New Medicines Will Be Featured in 55 Presentations
Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant. Enhertu data will reinforce potential to set new standards in HER2-targetable disease. Data for antibody drug conjugate datopotamab deruxtecan will demonstrate potential in HR-positive and triple-negative breast cancer.